E-Mail
IMAGE: Kenneth Grossmann, MD, PhD, of Huntsman Cancer Institute, led the SWOG S1404 clinical trial, which found that patients with high-risk melanoma who had pembrolizumab after their surgery had a longer. view more
Credit: Huntsman Cancer Institute
PORTLAND, OR - Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients three and one-half years after the last patient enrolled to the trial. They did find, however, that patients taking pembrolizumab had fewer serious side effects than those treated with either high-dose in
National Cancer Center Announces +20% Increase in Research Fellowship Awards
Share Article
Additional awards will support post-doctoral cancer research at the University of Pittsburgh, Boston Children’s Hospital and City of Hope National Research Center, California
“NCC increased its grant monies from $450,000 in 2019 to $570,000 in 2020 by 21% awarded to young post-doctorates who don’t have many other avenues of support. The innovative studies we fund are helping to advance our progress in immunotherapy and other cancer treatments.” Jerome Ritz, M.D. NEW YORK (PRWEB) March 15, 2021 The National Cancer Center is pleased to announce it has increased its 2020-21 research grant awards by +20%, resulting in the appointment of three additional research fellows to pursue promising and innovative cancer research. Each fellow initially receives $40,000 and will be eligible for an additional grant of $42,00